Vitaliy Kuznets
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Vitaliy Kuznets has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Victoria A. Serhiyenko
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2 shared publications - Volodymyr Sehin
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2 shared publications - Ludmila Serhiyenko
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
1 shared publication - Myroslav Baitsar
First Lviv Territorial Medical Association, St. Panteleimon Hospital, Lviv, Ukraine
1 shared publication О.о. Serhiyenko
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
1 shared publication
Latest Publications
- Open Access
- 19 June 2024
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 73 (1)
POST-TRAUMATIC STRESS DISORDER, INSOMNIA, HEART RATE VARIABILITY AND METABOLIC SYNDROME (NARRATIVE REVIEW)
This narrative review was aimed to analyze the scientific data about the association of post-traumatic stress disorder, insomnia, obstructive sleep apnea syndrome, dyssomnias, heart rate variability, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular autonomic neuropathy, along with potential pathophysiological mechanisms underlying these associations. The results of experimental, cohort, prospective, and randomized clinical studies provide evidence of common pathogenetic pathways contributing to their development. Searches were conducted in Scopus, Science Direct (from Elsevier), EBSCO, and PubMed databases, including the Medline databases. Additionally, a manual search of publication bibliographies was undertaken to uncover research outcomes not accessible through online searches.
- 19 June 2024
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 73 (1)
Open AccessPOST-TRAUMATIC STRESS DISORDER, INSOMNIA, HEART RATE VARIABILITY AND METABOLIC SYNDROME (NARRATIVE REVIEW)
This narrative review was aimed to analyze the scientific data about the association of post-traumatic stress disorder, insomnia, obstructive sleep apnea syndrome, dyssomnias, heart rate variability, metabolic syndrome, type 2 diabetes mellitus, and cardiovascular autonomic neuropathy, along with potential pathophysiological mechanisms underlying these associations. The results of experimental, cohort, prospective, and randomized clinical studies provide evidence of common pathogenetic pathways contributing to their development. Searches were conducted in Scopus, Science Direct (from Elsevier), EBSCO, and PubMed databases, including the Medline databases. Additionally, a manual search of publication bibliographies was undertaken to uncover research outcomes not accessible through online searches.
- Open Access
- 30 May 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (3) , 218-224
Melatonin and blood pressure: a narrative review
Melatonin has several impacts on the cardiovascular system, including the potential to reduce blood pressure in addition to its role in regulating sleep. It has the ability to decrease adrenergic system activity and indirectly enhance endothelial function. Melatonin can provide antihypertensive effects by stimulating own receptors in the central nervous system and peripheral arteries. In addition, melatonin is a potential treatment for patients with hypertension, including the “night-peaker” category. However, the results of only a few randomized trials suggest that melatonin supplements are effective in the treatment of hypertension. Melatonin can lower blood pressure due to vasodilatation, direct blocking of Ca2+ channels and increased production of nitric oxide in the endothelium; antioxidant properties; suppression of the sympathetic nervous system, reduction of norepinephrine production, as well as activation of the parasympathetic nervous system. Because the drug is usually taken at bedtime, it may increase the duration and quality of sleep and therefore lower blood pressure during sleep. Low endogenous melatonin secretion during sleep may be associated with elevated nocturnal blood pressure and comorbid cardiovascular diseases. In addition, melatonin exhibits an excellent safety profile. Consequently, larger-scale, longer-term studies with higher patient heterogeneity, biomarker identification, and idiosyncrasies related to melatonin use are required. The aim of this narrative review is to analyze the peculiarities of the mechanisms of action, as well as the effect of exogenous melatonin on blood pressure parameters in the experiment and clinic. The search was conducted in Scopus, Science Direct (from Elsevier), and PubMed, including the MEDLINE databases. The key words used were “melatonin,” “blood pressure”, “hypertension”, “obesity”, “metabolic syndrome”. We manually searched the bibliography of publications to find study results that the online search did not yield.
- 30 May 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (3) , 218-224
Open AccessMelatonin and blood pressure: a narrative review
Melatonin has several impacts on the cardiovascular system, including the potential to reduce blood pressure in addition to its role in regulating sleep. It has the ability to decrease adrenergic system activity and indirectly enhance endothelial function. Melatonin can provide antihypertensive effects by stimulating own receptors in the central nervous system and peripheral arteries. In addition, melatonin is a potential treatment for patients with hypertension, including the “night-peaker” category. However, the results of only a few randomized trials suggest that melatonin supplements are effective in the treatment of hypertension. Melatonin can lower blood pressure due to vasodilatation, direct blocking of Ca2+ channels and increased production of nitric oxide in the endothelium; antioxidant properties; suppression of the sympathetic nervous system, reduction of norepinephrine production, as well as activation of the parasympathetic nervous system. Because the drug is usually taken at bedtime, it may increase the duration and quality of sleep and therefore lower blood pressure during sleep. Low endogenous melatonin secretion during sleep may be associated with elevated nocturnal blood pressure and comorbid cardiovascular diseases. In addition, melatonin exhibits an excellent safety profile. Consequently, larger-scale, longer-term studies with higher patient heterogeneity, biomarker identification, and idiosyncrasies related to melatonin use are required. The aim of this narrative review is to analyze the peculiarities of the mechanisms of action, as well as the effect of exogenous melatonin on blood pressure parameters in the experiment and clinic. The search was conducted in Scopus, Science Direct (from Elsevier), and PubMed, including the MEDLINE databases. The key words used were “melatonin,” “blood pressure”, “hypertension”, “obesity”, “metabolic syndrome”. We manually searched the bibliography of publications to find study results that the online search did not yield.